Library · Oncology, infection & imaging · PET imaging of neuroendocrine tumors
Copper-64 Dotatate
64Cu-DOTATATE, Detectnet
FDA-approved (2020) radiopharmaceutical for PET imaging of somatostatin receptor-positive neuroendocrine tumors. Its longer half-life versus gallium-68 agents allows sharper imaging and simpler daily production.
Research score 88/100. Reference only, not a dose.
- Diagnostic Imaging
- US status
- Prescription Only - Diagnostic
- Approval
- FDA Approved (2020)
- Evidence
- 90.9% sensitivity, 96.6% specificity for detecting NETs
- Research score
- 88 / 100
- Indication
- PET imaging of somatostatin receptor-positive neuroendocrine tumors
- Origin
- United States
- Source category
- Diagnostic & Imaging
- Status group
- Approved / prescription
Mechanism
Binds preferentially to somatostatin receptor type 2, overexpressed on neuroendocrine tumor cells, and its copper-64 positron emission allows PET visualization of receptor-bearing tumors.
Safety file
Excellent safety record; no serious adverse events in trials, with minor reactions in under 2% of cases.
- Nausea (<2%)
- Vomiting (<2%)
- Flushing (<2%)